Vmat inhibitor contraindication

XENAZINE is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington's disease (1).

FDA-approved indication: Xenazine is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated

XENAZINE is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington's disease.

The most effective treatments for stuttering include second-generation antipsychotics, selective D1 antagonism, VMAT-2 inhibitors

Currently all drugs known to bind to the VMAT inhibit Although occasionally useful for these indications, VMAT2 inhibitors are accompanied by

Combining VMAT-2 inhibitors with monoamine oxidase inhibitors is discouraged because monoamine oxidase is needed to degrade presynaptic dopamine

The term VMAT 2 inhibitor, inhibiting VMAT 2, or inhibition of VMAT 2 Side effects of some drugs can cause depression. Family history of

Dexamphetamine (d-amphetamine) and lisdexamfetamine: D-amphetamine is a competitive inhibitor of DAT, NAT, and VMAT. Lisdexamfetamine is a

Other than stopping or switching antipsychotic medication, the strongest current evidence for TD treatment is the use of the VMAT inhibitors, deutetrabenazine